Drug compound preparation for treating Alzheimer's disease

A technology for Alzheimer's disease and compound preparations, applied in the field of medicine, can solve the problems of reducing drug safety and difficulty in long-term application, and achieve the effect of improving patient behavior and learning and memory functions, clear drug effects, and simple ingredients

Active Publication Date: 2014-07-30
沈阳百岁生物科技发展有限公司
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, studies have found that although these treatment measures can temporarily improve symptoms, they are difficult to apply for a long time due to their own limitations. For example, clinically applied western medicine may cause gastrointestinal adverse reactions such as nausea, diarrhea and vomiting while relieving symptoms; The treatment method of TCM syndrome differentiation also reduces the safety of the drug due to the complex components, so it is of great significance to research and develop new and effective drugs for the treatment of Alzheimer's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug compound preparation for treating Alzheimer's disease
  • Drug compound preparation for treating Alzheimer's disease
  • Drug compound preparation for treating Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] This embodiment provides a drug compound preparation for treating Alzheimer's disease, characterized in that: the main components of the drug compound preparation for treating Alzheimer's disease include epigallocatechin gallate and vitamin E;

[0044] Oil-soluble vitamin E is mixed with 1 volume of edible oil solution, and water-soluble EGCG is mixed with 2 volumes of distilled water; after the above two liquids are mixed, an emulsifier whose mass is 10% of the edible oil mass is added to form an oil-water mixture. Suspension, the mass fraction of EGCG is 0.1%, and the mass fraction of vitamin E is 0.3%.

[0045] The epigallocatechin gallate is a polyphenol component extracted from green tea or chemically synthesized.

[0046] The emulsifier is soybean lecithin or lecithin.

[0047] The drug compound preparation for treating Alzheimer's disease has the effect of reducing the aggregation of beta amyloid protein on D-galactose-induced Alzheimer's disease model mice. Th...

Embodiment 2

[0082] This embodiment provides a drug compound preparation for treating Alzheimer's disease, characterized in that: the main components of the drug compound preparation for treating Alzheimer's disease include epigallocatechin gallate and vitamin E;

[0083] Oil-soluble vitamin E is mixed with 1 volume of edible oil solution, and water-soluble EGCG is mixed with 2 volumes of distilled water; after the above two liquids are mixed, an emulsifier whose mass is 10% of the edible oil mass is added to form an oil-water mixture. Suspension, the mass fraction of EGCG is 0.02%, and the mass fraction of vitamin E is 0.3%.

[0084] The epigallocatechin gallate is a polyphenol component extracted from green tea or chemically synthesized.

[0085] The emulsifier is soybean lecithin or lecithin.

[0086]The drug compound preparation for treating Alzheimer's disease has the effect of reducing the aggregation of beta amyloid protein on D-galactose-induced Alzheimer's disease model mice. Th...

Embodiment 3

[0116] This embodiment provides a drug compound preparation for treating Alzheimer's disease, characterized in that: the main components of the drug compound preparation for treating Alzheimer's disease include epigallocatechin gallate and vitamin E;

[0117] Oil-soluble vitamin E is mixed with 1 volume of edible oil solution, and water-soluble EGCG is mixed with 2 volumes of distilled water; after the above two liquids are mixed, an emulsifier whose mass is 10% of the edible oil mass is added to form an oil-water mixture. Suspension, the mass fraction of EGCG is 0.2%, and the mass fraction of vitamin E is 0.3%.

[0118] The epigallocatechin gallate is a polyphenol component extracted from green tea or chemically synthesized.

[0119] The emulsifier is soybean lecithin or lecithin.

[0120] The drug compound preparation for treating Alzheimer's disease has the effect of reducing the aggregation of beta amyloid protein on D-galactose-induced Alzheimer's disease model mice. Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A drug compound preparation for treating Alzheimer's disease includes the main components of epigallocatechin gallate and vitamin E. Oil-soluble vitamin E is mixed with 1 part by volume of edible oil solution, and water-soluble EGCG is mixed with 2 parts by volume of distilled water; the two liquids are mixed and then added with an emulsifier in the weigh 10% of the edible oil, so as to form an oil-water suspension with mass fraction of EGCG of 0.02-0.1% and mass fraction of vitamin E of 0.3%. The invention has the advantage that the drug compound preparation has significant improvement on learning and memory impairment in an Alzheimer's disease mouse model induced by D-galactose, and can reduce the deposition of A beat 1-40 in the brain; and the drug compound preparation reduces antioxidation stress effect, anti-apoptosis effect and anti-inflammatory effect by increasing antioxidant enzymes, so as to exert the effect in resisting Alzheimer's disease. The drug compound preparation has simple composition, clear efficacy and easy preparation, can effectively play the roles of improving the behavior and learning and memory functions of patients, and does not generate other adverse reactions in large dose application.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a drug compound preparation for treating Alzheimer's disease. Background technique [0002] Alzheimer's disease is senile dementia, which is a progressive and fatal neurodegenerative disease. conduct disorder. With the acceleration of aging, the number of patients with Alzheimer's disease will increase sharply, which will bring a heavy burden to families and society, and gradually become a social problem. Therefore, the treatment of Alzheimer's disease has become a big problem to be solved urgently in the scientific community. [0003] The etiology and pathogenesis of Alzheimer's disease have not yet been elucidated, and there is no effective treatment so far. Its characteristic pathological changes are the formation of extracellular senile plaques in the cerebral cortex and hippocampus, intracellular neurofibrillary tangles, and neuron loss. Accompanied by gliosis, etc. Among them, t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/355A61P25/28A61K31/353
Inventor 魏敏杰刘明妍钟欣姚维范王爽王崴赵琳何苗赵海山
Owner 沈阳百岁生物科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products